Article

Wavefront-guided LASIK helpful tool for residual myopia

Stanford, CA-Wavefront-guided LASIK re-treatment procedures with the VISX CustomVue platform (VISX/Advanced Medical Optics [AMO]) seem to be effective, predictable, and safe in eyes with residual myopia using Fourier-based treatment software, reported Gloria Wang, MD.

Dr. Wang, chief resident at Stanford University, Stanford, CA, and colleague Edward Manche, MD, conducted a retrospective study in which they evaluated the CustomVue system and the effects of higher-order root mean square (RMS) values preoperatively and postoperatively.

Dr. Manche performed all surgeries using the VISX S4 excimer laser (VISX/ AMO) to treat patients who had previously undergone LASIK.

The mean preoperative spherical equivalent was –0.79 ± 0.50 D (range, –2.37 to 0.75 D). Three months after the enhancement surgery, the spherical equivalent decreased to –0.31 ± 0.36 D (range, –0.875 to +0.75 D), Dr. Wang reported.

No complications occurred. Of the 59 eyes, 57 eyes had been followed for 1 month and 31 eyes had 3 months of follow-up.

As expected, there was a decrease in the amount of myopia at 1 and 3 months postoperatively, with no significant difference between the two time points, Dr. Wang pointed out.

"The efficacy of the procedure was excellent; at 3 months postoperatively, 81% of eyes had 20/20 or better uncorrected visual acuity (UCVA) and 32% of eyes had 20/16 or better UCVA," Dr. Wang said. "The predictability was also excellent. All eyes were within 1 D of the target correction at the 3-month examination, and 81% of the eyes were within 0.5 D of the attempted correction at 3 months."

No eyes lost more than one line of best-corrected visual acuity (BCVA). Most eyes gained lines of BCVA 1 and 3 months after the enhancement procedure.

The analysis of higher-order aberrations showed that there was a decrease in the preoperative RMS from 0.39 ± 0.18 μm (range, 0.14 to 0.97 μm) to 0.35 ± 0.16 μm (range, 0.07 to 0.74 μm) 3 months after the enhancement. A reduction in coma was also observed from 0.22 μm preoperatively to 0.18 μm at the 3-month visit. The trefoil values were similar preoperatively and postoperatively at 0.13 μm and 0.12 μm, respectively. The spherical aberration decreased from 0.19 D preoperatively to 0.14 D at 3 months. No complications developed intraoperatively or postoperatively and there were no cases of epithelial ingrowth.

"Our results showed that the VISX CustomVue wavefront-guided re-treatment using Fourier-based treatment software in eyes that had undergone a previous LASIK procedure is effective, predictable, and safe for patients with residual myopia and compound myopic astigmatism," Dr. Wang said. "Analysis of higher-order RMS and aberrations showed a decreasing trend over time."

She noted, however, that longer follow-up is necessary to assess the stability of the refraction.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.